Tags:

Spero Therapeutics, Inc.


A securities class action has been filed against Spero Therapeutics, Inc. (SPRO) on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Spero securities between October 28, 2021 through May 2, 2022.  This case has been filed in the USDC – E.D.N.Y.

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements  and/or failed to disclose that: (i) the data submitted  in support of the Tebipenem HBr NDA were insufficient to obtain FDA approval; (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing  would  necessitate  a  significant  workforce  reduction  and  restructuring  of  Spero’s operations;  and  (iv)  as  a  result,  the  Company’s public  statements  were  materially  false  and misleading at all relevant times.

Tags:

Securities